Evidence map›Paper›PMID 38433331›Full record

ArticleCancer science2024

Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer.

Mayumi Kobayashi Kato, Erisa Fujii, Yuka Asami, Yukihide Momozawa, Kengo Hiranuma, Masaaki Komatsu, Ryuji Hamamoto, Takahiro Ebata, Koji Matsumoto, Mitsuya Ishikawa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Mayumi Kobayashi KatoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4065-0289
Erisa FujiiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0009-0004-0782-0922
Yuka AsamiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID https://orcid.org/0000-0001-5638-3504
Kengo HiranumaDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8197-4031
Masaaki KomatsuDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0421-8085
Ryuji HamamotoDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.
Takahiro EbataDepartment of Epigenomics, Life Science Tokyo Advanced Research Center, Hoshi University, Tokyo, Japan.
Koji MatsumotoDepartment of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6184-618X
Mitsuya IshikawaDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5371-706X
Tomoyasu KatoDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7569-7813
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5821-7400
Tokyo National Hospital · JPRIKEN Center for Advanced Intelligence Project · JPShowa University · JPHoshi University · JPRIKEN Center for Integrative Medical Sciences · JP

Funding

Grant-in-Aid for Scientific Research (C) 20K09636Grant-in-Aid for Young Scientists (B) 19K16572Grant-in-Aid for Young Scientists (B) 20K18207Japan Agency for Medical Research and Development 20ck0106554h0001Japan Agency for Medical Research and Development 23ama221520h0001National Cancer Center Research and Development Fund 2023-J-2
6 · The paper itself

Abstract

The clinical features of sporadic mismatch repair deficiency (MMRd) and Lynch syndrome (LS) in Japanese patients with endometrial cancer (EC) were examined by evaluating the prevalence and prognostic factors of LS and sporadic MMRd in patients with EC. Targeted sequencing of five LS susceptibility genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) was carried out in 443 patients with EC who were pathologically diagnosed with EC at the National Cancer Center Hospital between 2011 and 2018. Pathogenic variants in these genes were detected in 16 patients (3.7%). Immunohistochemistry for MMR proteins was undertaken in 337 of the 433 (77.9%) EC patients, and 91 patients (27.0%) showed absent expression of at least one MMR protein. The 13 cases of LS with MMR protein loss (93.8%) showed a favorable prognosis with a 5-year overall survival (OS) rate of 100%, although there was no statistically significant difference between this group and the sporadic MMRd group (p = 0.27). In the MMRd without LS group, the 5-year OS rate was significantly worse in seven patients with an aberrant p53 expression pattern than in those with p53 WT (53.6% vs. 93.9%, log-rank test; p = 0.0016). These results suggest that p53 abnormalities and pathogenic germline variants in MMR genes could be potential biomarkers for the molecular classification of EC with MMRd.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairEndometrial NeoplasmsTumor Suppressor Protein p53Uterine NeoplasmsAdultAgedAged, 80 and overDNA-Binding ProteinsEpithelial Cell Adhesion MoleculeFemaleHumansJapanMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1DNA-Binding ProteinsEpithelial Cell Adhesion MoleculeMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinTumor Suppressor Protein p53endometrial cancerimmunohistochemistryLynch syndromemismatch repair deficiencyMLH1 promoter methylationTP53

Identifiers

PMID38433331
PMCPMC11093186
OpenAlexW4392371961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.